As Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to spread, characterization of its antibody epitopes, emerging strains, related coronaviruses, and even the human proteome in naturally infected patients can guide the development of effective vaccines and therapies. Since traditional epitope identification tools are dependent upon pre-defined peptide sequences, they are not readily adaptable to diverse viral proteomes. The Serum Epitope Repertoire Analysis (SERA) platform leverages a high diversity random bacterial display library to identify proteome-independent epitope binding specificities which are then analyzed in the context of organisms of interest. When evaluating immune response in the context of SARS-CoV-2, we identify dominant epitope regions and motifs which demonstrate potential to classify mild from severe disease and relate to neutralization activity. We highlight SARS-CoV-2 epitopes that are cross-reactive with other coronaviruses and demonstrate decreased epitope signal for mutant SARS-CoV-2 strains. Collectively, the evolution of SARS-CoV-2 mutants towards reduced antibody response highlight the importance of data-driven development of the vaccines and therapies to treat COVID-19. Using a high throughput, random bacterial peptide display approach applied to patient serum samples, Haynes, Kamath, Bozekowski et al identify the antigens and epitopes that elicit a SARS-CoV-2 humoral response. They identify differences depending on disease severity and further in silico analysis suggests decreased epitope signal for Q677P but not for D614G mutant SARSCoV-2 strains.
【저자키워드】 Adaptive immunity, viral infection, Diagnostic markers, Data mining, 【초록키워드】 COVID-19, SARS-CoV-2, Coronaviruses, immune response, therapy, disease severity, Antibody Response, peptide, coronavirus 2, Antigen, Spread, specificity, Region, Patient, Evolution of SARS-CoV-2, Mild, D614G, proteome, mutant, in silico analysis, respiratory, epitope, Strains, platform, Therapies, dominant epitope, binding, SARSCoV-2, Bacterial, severe disease, humoral, cross-reactive, serum samples, neutralization activity, treat, organism, repertoire, random, motif, proteomes, antibody epitopes, Mutant SARS-CoV-2, approach, data-driven, highlight, analyzed, identify, applied, reduced, other coronavirus, elicit, infected patient, effective vaccine, the vaccine, SARS-CoV-2 epitope, 【제목키워드】 SARS-CoV-2 antibody, large cohort, epitope mapping, subject, with COVID-19,